🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

We are #hiring! 2 postdoctoral positions to join our endeavor to dissect circadian immunity in lung cancer. Check it out! European Research Council (ERC) #ERCJobs CNIO Stop Cancer

Extracellular targeted protein degradation: an emerging modality for drug discovery bit.ly/489BXVZ This new review by Jim Wells & Kaan Kumru covers systems for extracellular targeted protein degradation, including LYTACs, ATACs, AbTACs, PROTABs and KineTACs

Very excited by our results nature showing that IL4R signaling is strongly enriched in myeloid cells that infiltrate mice and lung cancer lesions nature.com/articles/s4158…

Congratulations!!!

A comprehensive Review by David Solit, Aphroditi Hanrahan and team on the ongoing fascinating journey to understand and conquer oncogenic RAF

Congratulations to Stuart A. Aaronson, MD: 2024 Jacobi Medallion Recipient youtu.be/7BXCQWFe5Qg?si… via YouTube Icahn School of Medicine at Mount Sinai

The June special issue is now available online. Tackling therapy resistance in cancer cell.com/trends/pharmac… Many thanks to the authors: @FredNatLab, WeichhartLab , Professor Zodwa Dlamini Christos Adamopoulos Canther_Lille, Jessica Konen, University of Illinois Chicago , Memorial Sloan Kettering Cancer Center Alex Zhavoronkov, PhD (aka Aleksandrs Zavoronkovs)

Cancer-promoting mutations are common in healthy tissue but rarely lead to tumour formation. A study of the mouse mammary gland reveals three protective mechanisms that limit the ability of cells to give rise to cancer go.nature.com/4dP12sd

BREAKING NEWS The 2024 #NobelPrize in Physiology or Medicine has been awarded to Victor Ambros and Gary Ruvkun for the discovery of microRNA and its role in post-transcriptional gene regulation.

John Jumper went from getting a PhD to getting a Nobel Prize in just seven years!

The Nobel prize website has a pretty well made 1-pager on how Alphafold works

Immune system one pager

nice

Our review article, "Resistance Mechanisms and Therapeutic Strategies for CDK4/6 Kinase Targeting in Cancer," is out today in Nature Cancer ! Check it out. rdcu.be/d75mG Evris Gavathiotis Christos Adamopoulos #PROTACs #CDK46 #CDK2 #Oncology #CancerImmunotherapy

New review article from Poulikos Poulikakos and colleagues, "Resistance Mechanisms and Therapeutic Strategies for CDK4/6 Kinase Targeting in Cancer," in Nature Cancer rdcu.be/d75mG Evris Gavathiotis Christos Adamopoulos #PROTACs #CDK46 #CDK2 #Oncology #CancerImmunotherapy

Delighted to contribute to this article on resistance mechanisms and therapeutic strategies targeting CDK4/6 kinases, and to collaborate with an amazing team driving new advancements in this field! Albert Einstein College of Medicine - Official Montefiore Health System nature.com/articles/s4301…

"More than 99% of new drug approvals (2010-2019) were funded by NIH. Why dismantle the engine that made the U.S. a world leader in innovation and drug development ? #DoNotDefundScience jamanetwork.com/journals/jama-…

A new chapter has begun for two of the world’s most popular preprint platforms, bioRxiv and medRxiv, with the launch of a non-profit organization that will manage them go.nature.com/41IRQkm

If you want to understand how cells function, you have to work out what proteins interact with — and where go.nature.com/4jqrs5Y

Scientists must push back against the threat of rising white nationalism and the dangerous and pseudoscientific ideas of eugenics go.nature.com/3EDa8fC